Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Bemarituzumab联合mFOLFOX6作为一线治疗方案用于FGFR2b过表达的东亚局部晚期或转移性胃/胃食管交界处癌患者：FIGHT研究最终分析的亚组分析
期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-024-01516-3
Kang, Yoon-Koo; Qin, Shukui; Lee, Keun-Wook; Oh, Sang Cheul; Kim, In-Ho; Kim, Jong Gwang; Li, Yong; Yan, Zhuchen; Li, Jin; Bai, Li-Yuan; Chan, Catherine; Yusuf, Akeem; Zahlten-Kümeli, Anita; Taylor, Kate; Yamaguchi, Kensei
